Last updated
Semaglutide is the established GLP-1 mono-agonist; retatrutide is the investigational triple agonist that adds GIP and glucagon on top. It is the widest mechanistic gap in the incretin field — and, importantly, one that has not been tested head-to-head. This page separates what the trials show from what they don’t.
Research reference only. Not medical advice, prescribing guidance, or a product recommendation.
| Dimension | Retatrutide | Semaglutide |
|---|---|---|
| Receptor targets | GIP-R + GLP-1R + glucagon-R | GLP-1R only |
| Agonism class | Triple agonist | Mono-agonist |
| Developer | Eli Lilly (LY3437943) | Novo Nordisk |
| Approval status | Investigational (Phase 3 — TRIUMPH) | FDA approved (2017 T2D · 2021 obesity) |
| Peak weight ↓ (trial) | ~24% (Phase 2, 48 wk, 12 mg) | ~15% (STEP-1, 68 wk, 2.4 mg) |
| Extra vs GLP-1 | GIP (insulinotropic) + glucagon (energy expenditure, liver fat) | — |
| Dosing | Once weekly (trial) | Once weekly (or daily oral) |
| Maturity of evidence | Phase 2 complete; Phase 3 ongoing | Multiple completed Phase 3 + CV outcomes |
~24% vs ~2% (placebo)
Mean body-weight change · n=338 · 48 wk — Jastreboff et al., NEJM 2023; highest-dose arm
−14.9% vs −2.4% (placebo)
Mean body-weight change · n=1961 · 68 wk — Pivotal obesity trial for Wegovy
In progress — not yet reported
Phase 3 efficacy/safety · Ongoing — Approval and any label depend on these outcomes
Retatrutide’s triple mechanism produced the largest mean weight reduction reported for an incretin agent in Phase 2 (~24%), above semaglutide’s pivotal STEP-1 figure (~15%). But these are separate trials at different doses, durations, and stages — not a head-to-head — so the gap is suggestive, not settled. Semaglutide is FDA-approved with completed Phase 3 and cardiovascular-outcome data; retatrutide is investigational, with its Phase 3 (TRIUMPH) results and full safety profile still pending. Treat the comparison as mechanism plus early data, not a ranking.
Semaglutide activates only the GLP-1 receptor. Retatrutide activates three receptors — GIP, GLP-1, and glucagon. The added GIP and glucagon arms are associated with a complementary insulin signal, increased energy expenditure, and hepatic fat reduction, and are the proposed basis for retatrutide’s larger Phase 2 weight loss.
In Phase 2, retatrutide reported ~24% mean weight reduction at the highest dose versus semaglutide’s ~15% in STEP-1 — but across different trials, not a direct comparison, and retatrutide’s Phase 3 results are not yet reported. It is premature to call one superior on head-to-head evidence, because none exists yet.
No. Retatrutide (LY3437943) is investigational and in Phase 3 (the TRIUMPH program). Semaglutide is FDA-approved as Ozempic, Rybelsus, and Wegovy.
Beyond GLP-1’s appetite and glycemic effects, glucagon-receptor agonism is studied for increased energy expenditure and hepatic lipolysis (liver-fat reduction). The trade-off is that glucagon can raise glucose, so a triple agonist must balance it against the insulinotropic GLP-1/GIP signals.
Mechanism, evidence, and trade-offs between Retatrutide and Semaglutide — citation-backed answers grounded in PubMed, PubChem, and ClinicalTrials.gov.